Scalper1 News
Horizon Pharma (HZNP) has turned down nearly 30 deals this year as it continues on the hunt for drug acquisitions, UBS said Friday as it raised its price target on Horizon Pharma stock as well as its revenue estimates. In a research report, UBS analysts Marc Goodman and Ami Fadia wrote that “because of its track record and balance sheet, (Horizon) has hit the radar of more potential sellers of assets.” With a market cap just over $5 billion, Scalper1 News
Scalper1 News